SLC5A2 and acute kidney injury: There was also considerable heterogeneity in the timing of SGLT2 inhibitor initiation, variability in AKI definitions (ranging from KDIGO and AKIN to undefined), and incomplete or inconsistent reporting of renal and safety outcomes.